AlphaMaven AlphaMaven

Isomorphic Labs breaks biotech VC fundraising record with $5B series C

Reported by Biospace
Nov 17, 2026· 2 min read
Save Post LinkedIn Email
Key Takeaways
  • • Isomorphic Labs raised $5 billion in Series C funding, more than doubling its $2.1 billion Series B from May and breaking the industry record for the largest single biotech venture round.
  • • The round was co-led by Greenoaks and Sequoia Capital, with continued investment from parent Alphabet, according to a Tuesday release. It surpasses Altos Labs' $3 billion debut in 2022.
  • • Proceeds will scale the company's AI drug design engine and fund its preclinical pipeline as it moves toward the clinic. Isomorphic has not publicly disclosed any clinical assets.
  • • Cumulative funding now totals at least $7.7 billion, all raised without a disclosed clinical program.
  • • Isomorphic has announced research partnerships with Novartis, Eli Lilly and Johnson & Johnson.
Summary
Isomorphic Labs has closed a $5 billion Series C funding round, a figure the company's own release and the reporting describe as the largest single raise in biotech venture capital history. The round, co-led by California-based investors Greenoaks and Sequoia Capital, included continued investment from Alphabet, the company's parent. The raise more than doubles the $2.1 billion Series B the London-based company closed earlier in 2026. Altos Labs, another AI-focused drug discovery company, previously held the record with a $3 billion debut in 2022.

According to the company, the new capital will scale its drug design engine, which it describes as a suite of foundational simulation AI models that work natively across multiple therapeutic areas and drug modalities. The funds will also support Isomorphic's preclinical pipeline as it prepares to enter the clinic. The company has not publicly disclosed any drug candidates, but says it has produced preclinical results for internal programs in oncology and immunology. The raise also runs counter to a recent investor trend toward more mature, de-risked assets, since Isomorphic has yet to disclose a molecule or reach clinical trials.

Founder and CEO Demis Hassabis, a 2024 Nobel laureate who co-founded Google DeepMind and serves as chief scientist for Alphabet, said in a prepared statement that the company's drug design engine is generating molecules with unprecedented precision and speed. He said the round will accelerate work on foundational biology models, deeper understanding of systemic disease, and the first therapeutic programs headed toward clinical trials. President Max Jaderberg said the company aims to unlock some of the hardest problems in drug discovery.

Isomorphic is also building an ecosystem of partners and global infrastructure it considers necessary to power AI-led bioengineering. The company has announced research partnerships with several large pharmaceutical companies, including Novartis, Eli Lilly and Johnson & Johnson. Isomorphic launched in 2021 and announced its first fundraise, $600 million, in March 2025. By the company's count in the reporting, it has raised at least $7.7 billion to date without disclosing a clinical program.

Go deeper than the headline

Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.

Start your free 7-day trial

Sources

1 outlet

AlphaMaven summarised this story from the reporting below. Each link opens the original article.

Biospace Isomorphic Labs breaks biotech VC fundraising record with $5B series C